Add this topic to your myFT Digest for news straight to your inbox
German group’s treatment is among only 9 candidates to have entered a phase 3 trial
Pharma group was accused of paying bribes to doctors and improperly funding drug purchases
Pandemic shows purpose can defy sceptics. Plus: six general counsel who stand out on sustainability
Shortages of antimalarials and inhalers feared as purchases spike
The Novartis boss realised he had to radically change his traditional management ideas
Sandoz reaches $195m criminal settlement with US DoJ related to four conspiracies
Drugs that treat rare diseases can be good for wealth as well as health
Novel gene therapy a boon to Swiss drugmaker
Two $2m treatments launch this year but a reluctance to fork out could dim investor enthusiasm
Twice-yearly injection of cholesterol-lowering medicine aims to save thousands of lives
Pharma focus on rare diseases has curbed investment in tackling common conditions
Prospering Chinese and Indian citizens could constitute a lucrative market
Swiss company looks to restock pipeline with acquisition of The Medicines Company
Five-year agreement is one of the most expansive tie-ups between big pharma and big tech
Company faces possible civil or criminal charges over manipulated Zolgensma data
US regulator investigates timing of revelation about studies behind world’s most expensive drug
Swiss drugmaker expects its China sales to overtake Europe
Company could face civil or criminal penalties over issue related to world’s priciest drug
Appetite for investment in sector grows beyond US
Paul Hudson, who ran Swiss group’s pharmaceuticals business, will take over in September
US FDA gives green light for $2.1m treatment of spinal muscular atrophy
Japanese drugmaker is looking to reduce its $48bn debt following Shire acquisition
The Swiss pharma group’s former subsidiary will fare better alone
A proposal by the Federal Reserve could force large foreign banks in the US to hold …
International Edition